CD82 and prostate cancer: This proposition is supported by the immunofluorescence staining data of human prostate cancer tissue specimens, which illustrated that CD82 was co-downregulated with E-cadherin during prostate cancer development, along with inversely upregulated mesenchymal proteins including Snail, α-SMA, and vimentin.